Clinical and biological studies on nodal marginal zone lymphoma (NMZL) are hampered by the lack of specific diagnostic markers and the low reproducibility of this diagnosis. A comparative expression-profiling study has shown a set of markers to be differentially expressed in NMZL compared with follicular lymphoma (FL), including myeloid cell nuclear differentiation antigen (MNDA), a nuclear protein expressed by myeloid cells and a subset of B-cells. The aim of this study was to characterize the expression of MNDA in normal and reactive human tissue, and in a large series of non-Hodgkin's B-cell lymphomas, with particular emphasis on NMZL and FL. Our results showed that MNDA is expressed in normal tissue by a subset of the marginal zone B cells. They also showed MNDA expression in subgroups of chronic lymphocytic leukemia, mantle-cell lymphoma, and diffuse large B-cell lymphoma, but MNDA was especially expressed by lymphomas derived from the marginal zone, such as mucosa-associated lymphoid-tissue lymphoma, splenic marginal-zone lymphoma and NMZL. MNDA expression was rarely observed in FL, a characteristic that is of potential value in distinguishing between NMZL and FL. MNDA expression is thus a useful tool for the recognition of NMZL.
Introduction
Nodal marginal zone lymphoma (NMZL) diagnosis lacks reproducibility because of the absence of characteristic markers, and distinguishing it from follicular lymphoma (FL) is still a biological and clinical challenge. A comparative expressionprofiling study has identified a set of markers that are differentially expressed in NMZL and FL, including myeloid cell nuclear differentiation antigen (MNDA), a highly basic nuclear protein (55 kDa) discovered using an immunoblot screening assay of nuclear proteins from leukemia cell lines. 1 This protein is the product of the MNDA gene, located on chromosome 1q22, which is a member of the interferon (IFN)-regulated 200 family of genes (HIN-200). These contain one or two copies of a partially conserved 200-amino-acid domain that is thought to mediate protein-protein interactions specifically with other transcription regulatory proteins. 2 Myeloid cell nuclear differentiation antigen is constitutively expressed in myelomonocytic leukemia cells, normal peripheral blood granulocytes and monocytes. 1, 3, 4 Although the expression of MNDA was initially thought to be restricted to the myelomonocytic lineage, several studies have shown the expression of this protein by normal and neoplastic B lymphocytes. [5] [6] [7] These findings, and the knowledge that NMZLs have no specific immunohistochemical markers and that those of FL (bcl6, CD10) are not always conclusive prompted us to develop a monoclonal antibody (mAb) that could work in paraffinembedded tissue with which we could investigate the potential diagnostic value of MNDA as a marker for NMZL, and as a differentiating tool for FL.
Thus, this study aimed to characterize MNDA expression at the protein level in normal and reactive human tissue and in a large series of non-Hodgkin's B-cell lymphomas, with particular emphasis on NMZL and FL.
Materials and methods
Gene expression profiling RNA isolation, cDNA microarray target preparation and hybridization. RNA expression was investigated in a selection of 16 NMZL and 8 FL cases. All the cases studied correspond to involved lymph nodes. Total RNA was extracted from frozen tumor samples using the Trizol reagent (Invitrogen, Carlsbad, CA, USA) and purified and treated with RNase-free DNase I using the RNeasy kit (Qiagen Inc., Valencia, CA, USA). Later, it was hybridized for gene expression profiling on the Whole Human Genome Agilent 1X44K Oligonucleotide Microarray for 12 NMZL cases and on the Whole Human Genome Agilent 4X44K Oligonucleotide Microarray for 4 NMZL and 8 FL cases following the manufacturer's instructions. The two platforms were comparable. Briefly, 1 mg of total RNA was amplified and fluorescence-labeled with Agilent's Low-RNA Input Fluorescence Linear Amplification kit (Agilent Technologies, Santa Clara, CA, USA). The cRNA product was hybridized following the manufacturer's instructions. Universal Human Reference RNA (Stratagene, La Jolla, CA, USA) was used as a reference. Scanning was carried out using the GenePix 4100A Microarray Scanner System (Axon Instruments, Molecular Devices, Sunnyvale, CA, USA) and data were collected with GenePix Pro 6.0 software (Axon Instruments). Values for all consistent duplicates were averaged, whereas inconsistent duplicates were discarded, and genes for which complete data were not available were excluded from further analysis.
Microarray data analysis
Raw microarray data were processed as previously described. [8] [9] [10] Data from 16 NMZL cases were normalized against the expression for each gene from eight FL samples. Only the data from genes for which at least 50% of the data were available in the control samples were normalized; all other genes were excluded from the analysis. Genes were ranked according to their marker coefficient (MC), average t-test results, NMZL average, and the difference between the NMZL and FL averages. A full report of the results of this analysis will be published separately.
Production of monoclonal MNDA antibody
A cDNA encoding the full-length human MNDA protein was purchased from Origene (OriGene Technologies, Rockville, MD, USA). MNDA gene was amplified by PCR and introduced into the pCOLDII expression vector (Takara, Shiga, Japan). The 6 Â His-MNDA fusion protein was then expressed in Escherichia coli strain Rosetta (Novagen, San Diego, CA, USA) at 15 1C for 48 h. The recombinant protein was solubilized from its insoluble inclusion bodies in 20 mM Tris-HCl containing 0.5 M NaCl, 5 mM imidazole, 1 mM 2-mercaptoethanol and 6 M guanidineHCl (pH 8.0), and purified by affinity chromatography on a HiTrap Chelating column (GE Healthcare, Little Chalfont, UK) under denaturing conditions. Renaturation of the protein was induced on-column by decreasing the urea concentration over a linear gradient from 8 to 0 M over 3 h. After refolding, the renatured protein was eluted by gradually increasing the concentration of imidazole up to 0.5 M in 20 mM Tris (pH 8.0), 0.5 M NaCl and 1 mM 2-mercaptoethanol. The fractions containing MNDA were collected and concentrated using Vivaspin centrifugal filter devices (Vivascience, Hanover, Germany). Three BALB/c mice were injected intraperitoneally (thrice at 14-day intervals) with 100 mg 6 Â His-MNDA fusion protein and Freund's adjuvant. A 150-mg booster of the recombinant MNDA protein was injected intraperitoneally, and fused 3 days later, as described earlier.
11 Hybridoma supernatants were screened by ELISA. The mouse mAb that was raised against MNDA (clone 253) was cloned by the limiting dilution technique. Animal experiments were carried out under the experimental protocol approved by the Institutional Committee for Care and Use of Animals, CEUCA No. 001/02.
Tissue samples and preparation for tissue microarrays
All tissues were obtained from the tissue archives of the CNIO Tumor Bank. Donor tissue blocks were histologically sufficient. Samples were fixed in 4% buffered formalin and embedded in paraffin. A fresh cut and H&E-stained slide from each block was used for histological review and representative areas were selected. A Tissue Arrayer device (Beecher Instruments, Sun Prairie, WI, USA) was used to construct several tissue microarray (TMA) blocks, according to conventional protocols. 11 Standard tissue sections were analyzed in all NMZL, MALT and SMZL cases. Reactive inflammatory tissue was analyzed from different specimens corresponding to non-malignant mesenteric lymph nodes, tonsils, bone marrow and spleen.
A large series (517 cases) of human non-Hodgkin's lymphomas was investigated. The diagnosis of the TMA tissue was confirmed histologically in all cases by a central review using standard tissue sections. All cases corresponded to initial diagnostic biopsies before treatment. The histological criteria used for diagnoses and classification of cases were those of the World Health Organization Classification. 12 Some of these cases have been included in earlier studies. 13 
Antibodies
The other antibodies (Abs) used were activation-induced cytidine deaminase (AID) (JUA51E clone, undiluted, CNIO 
Western blotting
For total protein extraction, cell pellets were lysed in RIPA buffer supplemented with protease and phosphatase inhibitors. Protein extracts were resolved on 12% SDS-PAGE and electrotransferred to a Hybond-ECL nitrocellulose membrane (Amersham Pharmacia Biotech, Arlington Heights, IL, USA), blocked and probed with Abs against MNDA. After washes, membranes were incubated with HRP-conjugated secondary Abs (Dako) (dilution 1:200). Chemiluminescence was detected by incubating membranes with ECL-reagent (Amersham Pharmacia Biotech).
Immunostaining techniques
Myeloid cell nuclear differentiation antigen immunohistochemical staining was performed as follows: 2-to 4-mm-thick paraffinembedded TMA and complete tissue sections were cut onto Dako slides (Dako), and subsequently dewaxed, rehydrated, and subjected to antigen retrieval using the Dako's PT Link with 10 mM of sodium citrate, at pH 6, and heated at 95 1C. The slides were cooled and treated with peroxidase-blocking solution (Dako) for 5 min. Sections were then immunostained with MNDA (clone 253) mAb by the two-stage peroxidase-based EnVision technique (Dako), counterstained with hematoxylin, and mounted. Incubations, either omitting the specific Ab or containing unrelated Abs, were used as a control of the technique.
Double immunoenzymatic labeling
Double immunoenzymatic labeling of paraffin sections was performed using a standard BOND system protocol with the Abs MNDA/CD20, MNDA/CD3, MNDA/CD23, MNDA/CD68, MNDA/IgM and MNDA/IgD (Leica, Milton Keynes, UK).
Immunoperoxidase technique combined with immunofluorescence
Immunoperoxidase staining, combined with single or double immunofluorescence labeling, was carried out on paraffin sections of normal spleen and reactive mesenteric lymph nodes following a method that was described previously. 14, 15 Briefly, slides were immunostained for MNDA by the two-stage peroxidase-based EnVision technique, washed in phosphate buffered saline (PBS) for up to 5 min, then incubated in normal human serum for up to 10 min before immunofluorescence labeling with Abs CD27 (red) and IgD (green) in normal spleen and reactive mesenteric lymph node (triple staining), and IgM (green) and CD20 (green) in normal spleen and reactive mesenteric lymph node (double staining). Immunofluorescence labeling was carried out as described previously. 15, 16 Sections were incubated for 45 min at room temperature with a pair of Abs that were either from different species or of different immunoglobulin isotypes or subclasses. Sections were washed in PBS for up to 5 min, incubated in the dark for 45 min with secondary Abs (specific for species, isotype, or subclass) and labeled with contrasting green and red fluorochromes (Alexa Fluor 488 and Alexa Fluor 594, dilution 1:100). The slides were washed in PBS for up to 5 min, and mounted in fluorescent mounting medium (Dako) containing 1 mg/ml DAPI (4,6-diamidino-2-phenylindole).
Slides were examined on a Nikon E800 Eclipse fluorescence microscope (Nikon, Kingston-upon-Thames, UK) equipped for epifluorescence. Fluorescence images were captured with an Axiocam charge-coupled device (CCD) camera (Zeiss, Jena, Germany) and Axiovision software (Imaging Associates, Bicester, UK), and adjusted using Photoshop version 10.0 (Adobe, San Jose, CA, USA). 15 The immunoperoxidase image was viewed by transmitting light microscopy, and corresponding gray-scale images were inverted and pasted into the blue (or red in cHL) channel of the red-green-blue (RGB) Photoshop image. By means of this technique, cells expressing MNDA were visualized in blue (except in one case of normal spleen, which was visualized in red), whereas the immunofluorescence labeling marker was detected in green or red.
Scoring MNDA expression
Myeloid cell nuclear differentiation antigen protein expression was assessed by immunohistochemistry on normal as well as neoplastic human tissue microarrays and on complete sections. Each case was scored semi-quantitatively, depending on the number of positive cells, as negative (0-15% positive tumor cells) or positive (15-100% positive tumor cells).
All hematoxylin and eosin and immunohistochemistry slides were studied using an Olympus BX41 microscope (Olympus Europe, Barcelona, Spain) equipped with 20/0.40 and 40/0.65 objective lenses. Images were photographed using an Olympus DP70 camera (Olympus Europe) and Axiovision version 4.6 (Imaging Associates), and adjusted using Adobe Photoshop version 10.0 (Adobe Systems).
Results

Gene expression of NMZL and FL
Gene expression profiling of NMZL cases showed stronger expression of the MNDA gene than observed in FL cases. In fact, MNDA had the highest marker coefficient (MC) of all genes compared. It is of note that genes that were strongly expressed in the FL gene signature, such as KLHL6, BCL6, GCET1, and CD10, were ranked in positions 1018, 6004, 7300, and 7679, respectively. The intensity of MNDA gene expression in NMZL, although not the highest, showed the greatest difference between NMZL and FL expression among genes with a high level of expression (over 5.0). In addition, the difference in the MNDA gene expression in NMZL cases compared with FL cases was statistically significant, with an FDR value of 0.029 (Table 1) .
Validation of MNDA
To confirm that MNDA mAb (clone 253) recognized the human MNDA protein, immunohistochemistry was carried out on frozen cytospin preparations of V5-tagged human MNDA expressed in HEK293T (Figure 1) . Labeling with the anti-V5 mAb confirmed the efficiency of transfection. A cytospin preparation of V5-tagged human TdT protein was used as a negative control.
These results were confirmed by western blot using the cell lysate of MNDA and TdT-transfected cells, reactive tonsil and HL60 cell line. A 55-kDa band specific to the MNDA protein was observed in MNDA-transfected cells, reactive tonsil and HL60 cell line. Additional confirmation was obtained by immunohistochemistry, using a reaction containing MNDA protein control. We have used two different protein concentrations: 0.1 mg of MNDA Ab plus 0.75 mg, and 1.5 mg of recombinant MNDA protein. No MNDA staining was detected in the slides preincubated with the Ab plus the protein control, thus confirming the specificity of MNDA Ab.
MNDA protein expression in normal human tissue
Myeloid cell nuclear differentiation antigen protein expression in normal human tissue was analyzed on paraffin-embedded tissue sections using the anti-MNDA mAb (clone 253). MNDA protein was detected in the nucleus of mature granulocyte and monocyte cells of all the tissue samples used with great intensity, a distinct internal control. Moreover, MNDA was expressed, although with less intensity, by cells occupying the marginal zone surrounding the germinal centers (GCs) in normal tonsil. In reactive mesenteric lymph nodes, as well as in spleen tissue, where the marginal zone is known to be prominent, the expression of MNDA was also restricted to the marginal zone ( Figure 1) . The GCs of all follicles were negative for MNDA. Reactive monocytoid B cells and plasma cells did not express MNDA. Double fluorescence techniques showed that MNDApositive marginal zone cells were CD3(À), CD20( þ ), IgM( þ ), IgD(À), CD27( þ ) B cells, with a very small percentage of CD3(À), CD20( þ ), IgM( þ ), IgD( þ ), CD27(À) cells located within the mantle zone. The results obtained from double immunostaining techniques of MNDA and AID were of particular interest. AID has recently been identified as an essential enzyme for somatic hypermutation and class-switch recombination, and it is reported to be almost exclusively expressed by GC cells. 17, 18 Our results clearly showed that marginal zone cells of spleen and of reactive mesenteric lymph nodes were AID-negative and MNDA-positive 19 ( Figure 2 ). In the normal bone marrow, only myeloid cells, macrophages and monocyte cells were found to express MNDA.
MNDA protein expression in human lymphomas
The immunostaining results from paraffin sections of 517 cases of human non-Hodgkin's B-cell lymphomas are summarized in Table 2 .
Myeloid cell nuclear differentiation antigen was expressed in 23 of 35 chronic lymphocytic leukemia (CLL) cases (65%), 61 of 74 mantle-cell lymphoma (MCL) cases (82%), 10 of 12 lymphoplasmacytic lymphoma (LPL) and 34 (25 of ABC type) of 75 diffuse large B-cell lymphoma (DLBCL) cases (45%). In all these cases, MNDA had predominantly strong and diffuse expression (Figure 3) . Most of the hairy-cell leukemia (HCL) cases expressed MNDA (6/9). LPL-positive cases showed MNDA staining restricted to the small-cell component, whereas plasma cells were negative.
In 19 out of 20 (95%) cases of mucosa-associated lymphoid tissue (MALT) lymphomas, MNDA was strongly expressed in the marginal zone, in interfollicular areas and in intraepithelial lesions. All 20 (100%) cases of splenic marginal zone lymphoma (SMZL) expressed MNDA in the marginal zone and in the red pulp cords and sinuses (Figure 4) .
Fifty-seven NMZL cases were reviewed and analyzed for MNDA expression ( Figure 5 ). Mutational analysis data were available for five of these cases from earlier studies. 13 IgV H gene mutations were observed in four cases, with o98% homology; one case had no mutations, with 100% homology. MNDA was expressed in 43 (75%) cases, including all four IgV H mutated cases.
Myeloid cell nuclear differentiation antigen was strongly positive with a distinct pattern. MNDA-positive neoplastic cells, which had a mainly centrocyte-like morphology with some scattered larger cells, predominantly occupied the expanded neoplastic marginal zone, the adjacent interfollicular areas, and quite often colonized GCs. When the colonization was complete, the follicles were immunoreactive for MNDA and bcl2, and uniformly negative for bcl6 and CD10. CD23 showed a disrupted follicular dendritic cell network. Follicles with partial colonization showed a 'moth eaten' expression of MNDA in neoplastic cells, and of CD10 as well as bcl6 in normal GC cells.
MNDA-positive NMZL cases showed heterogeneous immunoexpression of other markers, 9 of 36 (25%) cases were CD43( þ ), 5 of 38 (13%) were CD5( þ ), and 13 of 41 (32%) were IgD( þ ). p53 expression was seen in 3 of 31 (10%) cases. Morphologically, plasmacytic differentiation was observed in 13 out of 41 (32%) cases.
Heterogeneity was also observed in MNDA-negative NMZL cases: of the 14 cases, 2 (14%) were CD43( þ ), 2 (14%) were CD5( þ ), and 9 (64%) were IgD( þ ). p53 was expressed in 1 of 11 (10%) cases, and plasmacytic differentiation was described in 2 of 14 (14%) cases .
Finally, MNDA expression was studied in 184 FL cases. Positivity was shown in only 9 (5%) cases, with heterogeneity of the intensity and pattern of staining. We then further investigated these nine cases with immunomarkers for bcl6, CD10, bcl2 and MUM1 proteins, and molecular studies for BCL2 gene translocation t(14;18) (FISH analysis) ( Table 3) .
Myeloid cell nuclear differentiation antigen was expressed in the neoplastic follicles of all four MUM1( þ ) cases at a lower intensity than that observed in the marginal zone ( Figure 6 ). All four cases were grade 3a: one featured the t(14;18) translocation, whereas the other three did not. The other MNDA-positive FL cases strongly expressed MNDA in the thin marginal zone rim and only in a few scattered centrocyte-like cells in the follicles. Of particular note is the marginal zone differentiation, by which FL cells 'invade' the surrounding marginal zone ( Figure 6 ).
For evaluating the potential diagnostic utility of MNDA staining in bone marrow biopsies, a set of SMZL and FL cases was investigated in bone marrow sections. Nine SMZL cases 
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show distinct MNDA staining, whereas none of the five FL cases investigated in the bone marrow showed expression of MNDA. A group of splenic follicular lymphoma cases was then investigated, 20 including 17 cases. Seven of them showed MNDA staining, confirming the distinctive nature of these extranodal FL cases.
Discussion
Myeloid cell nuclear differentiation antigen gene is a member of the human HIN-200 gene family, along with IFI16 (IntereferonInducible protein 16), AIM2 (Absent In Melanoma 2) and IFIX (IFN-inducible protein X) gene. The HIN nomenclature describing their expression, IFN-induction, nuclear localization and characteristic 200-amino-acid domains was adopted. 21 MNDA is located on chromosome 1q22, before IFI16 and AIM2, and its protein contains a PAAD/DAPIN/Pyrin domain at its N-terminus, followed by a copy of a C-terminal 200A domain.
The PAAD/DAPIN/Pyrin is the fourth member of the death domain superfamily, and has been claimed to be involved not only in apoptosis but also in the regulation of innate immunity and other processes, 22 regulating protein interactions involved in apoptotic (NF-kB) and inflammatory (caspase-1) signaling pathways. 23 This domain was identified in pyrin, and other proteins, such as an a-helical protein-protein interaction motif, and was simultaneously classified as a PAAD 24 and DAPIN domain. 25 The MNDA protein self-associates through its PAAD/ DAPIN/Pyrin domain, which is consistent with its putative involvement in protein-protein interactions.
Myeloid cell nuclear differentiation antigen has been detected in a variety of hematopoietic tissues, and is constitutively expressed in the myelomonocytic lineage, including monocytes and granulocytes. 3 However, MNDA is induced in Daudi Burkitt's lymphoma cells when treated with IFN-a, indicating expression of MNDA by lymphoma cells. 5 Miranda et al. 6 also described MNDA expression in normal B-cell subsets and in B-cell lymphomas, which is a further indication that expression is not limited to myelomonocytic lineage. In addition, Joshi et al. provided evidence of MNDA expression in B cells, whereby MNDA, ATM and CTLA4 genes were found to be overexpressed and associated with good clinical outcome in a subgroup of CLL patients who had low CD38 expression. Our study adds to the evidence of MNDA expression by B-cell lymphomas both at the gene level, with gene expression profile data, and at the protein level, using a newly generated mAb (clone 253) suitable for immunohistochemical staining of paraffin-embedded tissue sections, carried out on a large number of non-Hodgkin's lymphomas and normal tissue. Initially, we attempted to characterize the normal cell population expressed by MNDA protein on normal tonsil, reactive mesenteric lymph node and spleen. We showed that the cells expressing MNDA were CD20( þ ), IgM( þ ), IgD(À) and CD27( þ ) B cells, with a few exceptions of IgD( þ ), and CD27(À) cells. Most MNDA-positive cells were restricted to the supposed marginal zone area, which was prominent in the tissue samples used. Some cells, mainly IgD( þ ) and CD27(À), occupied the mantle zone. These results concur with the current view that the majority of the cells in the mixed B-cell population of the marginal zone are IgM( þ ), IgD(À) and CD27( þ ). 26, 27 No MNDA-positive B cells were found in the GC.
Activation-induced cytidine deaminase is an enzyme required for somatic hypermutation to take place in the GC. Willenbrock et al. 19 analyzed AID expression immunohistochemically to establish whether splenic marginal zone cells express this protein, thereby raising the possibility of somatic hypermutation in the MZ. They found no expression of AID in MZ cells. We also studied this protein to identify possible MNDA-positive cells that could express AID, not only in spleen but also in mesenteric lymph nodes. We found no MNDA-positive cells expressing AID in any of the cases studied. Scattered extrafollicular cells positive for AID were MNDA-negative, suggesting that MNDA expression was not related to AID expression.
Gene expression profile data comparing NMZL and FL showed MNDA overexpression in most NMZL cases and null or weak expression in the majority of FL cases. This extra-GC distribution of the MNDA expression is consistent with the findings of Miranda. 6 Indeed, most of our results from this study show MNDA expression by lymphomas other than FL. In CLL, 65% of the cases show positivity in MNDA with a diffuse pattern of expression, which is consistent with the data of Joshi et al. 7 , who showed a better outcome for patients overexpressing MNDA.
The postulated cell of origin in MCL is a pre-GC naïve B cell, which is a type not derived from the GC. 12 The prevalence of expression of MNDA in this lymphoma type was high (82%), similar to that found by Miranda et al. 6 in a smaller number of cases.
DLBCL, according to the Hans algorithm, can be divided into GC and non-GC types. In our study, 25 of 34 (73%) MNDApositive cases were of the non-GC type, indicating the preferential expression of MNDA in lymphoma types derived from cells outside the GC.
Lymphomas originated from the normal counterpart of marginal zone cells such as MALT lymphomas, SMZLs and NMZLs express MNDA with an increased frequency, an expected result because MNDA is known to be a marginal zone cell B-cell marker. Nevertheless, cases diagnosed as NMZL favorable outcome in CLL suggests that MNDA expression could be related to SHM. 7 The characteristics of the few NMZL cases studied here are consistent with this, but the size of the sample is too small to allow the conclusion that MNDA is associated with SHM to be drawn with confidence. All these data support the notion that NMZL is a heterogeneous lymphoma entity.
Myeloid cell nuclear differentiation antigen gene and protein expression was only expressed by a small group of FL cases (5%), although, as mentioned, it was never observed in the GC of normal tissue. This is not surprising as the gene expression profile showed some MNDA expression in a small number of FL cases. These MNDA-positive FL cases, when reviewed, were also positive for MUM1, a post-GC marker, and showed histological grade 3a. Most of them also showed expression of CD10 and lacked the t(14;18) translocation. These FLs are considered by Karube et al. 30 to be a different type of FL on the basis of their biological and clinical features. The data provided here seem to confirm that there is a subset of FL with distinct features that probably should be considered separately.
Marked marginal zone differentiation often occurs in FL and at times is so pronounced that it is difficult to distinguish it from NMZL with follicular colonization on morphological grounds. In such cases, MNDA has proved to be a reliable differential marker as it is expressed with a distinctive pattern in NMZL follicular colonization, when compared with FL with marginal zone differentiation.
In conclusion, we found MNDA to be a useful marker for the analysis of normal marginal zone cells and the diagnosis of NMZL cases, with a very restricted expression in FL. This is of potential value in the analysis of normal B-cell subpopulations and for discriminating between NMZL and FL. MNDA expression also offers the possibility of delineating more precisely the group of FL cases by additionally taking MUM1 expression into account. The biological role and further diagnostic applications of MNDA need to be more deeply explored.
